Zoetis Inc. (ZTS) Stock Price & Analysis
Zoetis Inc. (ZTS) closed at USD 82 on Thursday, October 22, 2026, up 2.99% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 79.62; the Oct 22, 2026 session ranged USD 79.91–82.29 on volume of 4,827,163 shares. Market capitalization is $33.88B, with a 52-week range of USD 68.77–147.93 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:16 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ZTS.md
Key facts (ZTS)
- Last four reported quarters (through Jun 30, 2026): revenue $9.52B, net income $2.62B (27.5% margin), free cash flow $2.32B (SEC filings).
- Valuation: P/E 13.0x (avg 29.9x at the last 3 fiscal year-ends), net debt $7.37B.
- 5 of 80 tracked superinvestors hold ZTS (13F, Q2 2026): 2 new, 1 added, 2 reduced, 0 unchanged.
- Analysts: Buy (mean 2.47 on a 1–5 scale) (17 analysts), mean target USD 93 (range 74–155).
- Total return with dividends: 1Y -42.9% vs S&P 500 +14.9%; 5Y -58.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.51, revenue estimate $2.30B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ZTS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B | $9.52B |
| Gross profit | $5.47B | $5.63B | $5.98B | $6.54B | $6.80B | — |
| Net income | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B | $2.62B |
| EPS (diluted) | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 | — |
| Free cash flow | $1.74B | $1.33B | $1.62B | $2.30B | $2.28B | $2.32B |
| Gross margin | 70.4% | 69.6% | 70.0% | 70.6% | 71.8% | — |
| Net margin | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% | 27.5% |
| Revenue growth | +16.5% | +3.9% | +5.7% | +8.3% | +2.3% | — |
| Cash + short-term investments | — | $3.58B | $2.04B | $1.99B | $2.45B | — |
| Total debt | $6.59B | $7.90B | $6.56B | $6.57B | $9.04B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ZTS)
P/E 13.0x · P/S 3.6x · EV/Sales 4.3x · P/FCF 14.6x · P/B 10.8x · FCF yield 6.84% · Earnings yield 7.72% · Buyback yield (TTM) 10.75% · Net debt $7.37B · EV $41.3B
P/E at fiscal year-ends: Dec 2025 20.9x, Dec 2024 29.8x, Dec 2023 38.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (ZTS)
5 of 80 tracked investors hold ZTS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Tweedy Browne | 3.03% | $40.0M | New position | |
| Ruane Cunniff | Ruane Cunniff LP | 2.63% | $169M | Reduced -3.0% |
| Mairs & Power | Mairs & Power Funds | 0.31% | $33.6M | Added +54.2% |
| Polen Capital | Polen Capital Management | 0.20% | $23.0M | Reduced -92.4% |
| Thomas Gayner | Markel Group | 0.04% | $4.8M | New position |
Analysts (ZTS)
Consensus Buy (mean 2.47 on a 1–5 scale), 17 analysts; mean target USD 93 (low 74, high 155).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Jefferies | Downgrade | Buy → Hold | $103 → $83 |
| 2026-10-16 | Goldman Sachs | Initiated | Neutral | $74 |
| 2026-08-25 | TD Cowen | Target lowered | Buy | $104 → $94 |
| 2026-08-20 | Stifel | Target lowered | Hold | $85 → $80 |
| 2026-08-11 | Citigroup | Target lowered | Buy | $112 → $96 |
| 2026-08-11 | BNP Paribas | Target lowered | Outperform | $146 → $110 |
| 2026-08-10 | Piper Sandler | Target lowered | Neutral | $90 → $80 |
| 2026-08-07 | UBS | Target lowered | Neutral | $85 → $80 |
| 2026-08-07 | JP Morgan | Target lowered | Overweight | $130 → $115 |
| 2026-08-06 | William Blair | Downgrade | Outperform → Market Perform | |
| 2026-07-27 | UBS | Target lowered | Neutral | $99 → $85 |
| 2026-07-22 | Morgan Stanley | Target lowered | Overweight | $115 → $99 |
Total return (dividends reinvested) (ZTS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -42.9% | -58.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -43.0% | -16.1% |
| Volatility (annualized) | 40.5% | 31.7% |
| Max drawdown | -52.3% (Oct 2025→Oct 2026) | -69.8% (Dec 2021→Sep 2026) |
ZTS revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U.S. | $1.27B | 51.3% | -6.6% |
| International | $1.17B | 47.5% | +8.1% |
| Total revenue | $2.47B | 100% | — |
ZTS revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Total products and services | $2.44B | 98.8% | -0.1% |
| Dogs and Cats | $1.63B | 66.2% | -4.9% |
| Companion Animal | $1.04B | 42.3% | -11.2% |
| Parasiticides | $698.0M | 28.3% | +5.8% |
| Vaccines | $521.0M | 21.1% | +2.2% |
| — Livestock (part of Vaccines) | $222.0M | 9.0% | +23.3% |
| — Swine (part of Vaccines) | $117.0M | 4.7% | -0.8% |
| — Fish (part of Vaccines) | $83.0M | 3.4% | +2.5% |
| — Horses (part of Vaccines) | $74.0M | 3.0% | +4.2% |
| — Sheep and other (part of Vaccines) | $26.0M | 1.1% | +4.0% |
| Dermatology | $398.0M | 16.1% | -15.9% |
| Cattle | $390.0M | 15.8% | +20.7% |
| — Other pharmaceutical (part of Cattle) | $168.0M | 6.8% | -4.0% |
| — Animal health diagnostics (part of Cattle) | $123.0M | 5.0% | +11.8% |
| — Other Non Pharmaceuticals (part of Cattle) | $70.0M | 2.8% | +2.9% |
| — Contract manufacturing & human health (part of Cattle) | $29.0M | 1.2% | -12.1% |
| Anti-infectives | $244.0M | 9.9% | +9.9% |
| Pain and sedation | $217.0M | 8.8% | -2.7% |
| Poultry | $115.0M | 4.7% | +10.6% |
| Total revenue | $2.47B | 100% | — |
ZTS revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Total geographical area | $2.44B | 98.8% | -0.1% |
| United States | $1.27B | 51.3% | -6.6% |
| Other emerging markets | $269.0M | 10.9% | +20.6% |
| — Brazil (part of Other emerging markets) | $103.0M | 4.2% | +10.8% |
| — Australia (part of Other emerging markets) | $94.0M | 3.8% | +13.3% |
| — Canada (part of Other emerging markets) | $72.0M | 2.9% | +1.4% |
| Other developed markets | $187.0M | 7.6% | +6.9% |
| — Germany (part of Other developed markets) | $69.0M | 2.8% | +21.1% |
| — Spain (part of Other developed markets) | $43.0M | 1.7% | +7.5% |
| — Japan (part of Other developed markets) | $41.0M | 1.7% | -4.7% |
| — Chile (part of Other developed markets) | $34.0M | 1.4% | +0.0% |
| United Kingdom | $72.0M | 2.9% | -11.1% |
| China | $62.0M | 2.5% | -7.5% |
| Mexico | $47.0M | 1.9% | +20.5% |
| France | $40.0M | 1.6% | -4.8% |
| Italy | $40.0M | 1.6% | +8.1% |
| Total revenue | $2.47B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ZTS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Pfizer (PFE) | “Under the Patent and Know-How License Agreement (Pfizer as licensor) Pfizer licenses to us certain of its intellectual property.” |
Quoted from the company's 10-K filed Feb 12, 2026.
ZTS customer concentration
In the period ended Dec 31, 2025, a single direct customer accounted for 16% of revenue, per the company's 10-K filed Feb 12, 2026. The company does not name it.
ZTS company outlook (results filed Aug 6, 2026)
- “Guidance to $9.120 - $9.320 Billion to Organic Operational Revenue Growth of (3)% to (1)% • Revises Full Year 2026 Adjusted Net Income Guidance to Organic Operational Growth of (9)% to (5)% • Revises Guidance for Adjusted Diluted EPS to $6.15 - $6.25 PARSIPPANY, N.J. – August 6, 2026 – Zoetis Inc .”
Quoted word-for-word from the SEC 8-K results press release.
ZTS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.51 | $1.84 | -18.3% | $2.30B | 13 |
| Next quarter (ends Dec 2026) | $1.31 | $1.64 | -20.3% | $2.24B | 12 |
| Current fiscal year (ends Dec 2026) | $6.21 | $6.87 | -9.6% | $9.25B | 14 |
| Next fiscal year (ends Dec 2027) | $6.45 | $7.39 | -12.8% | $9.39B | 15 |
ZTS options: expected move
Options price a move of about ±11.1% (±$9.10) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 45.6% | ±11.1% |
| Dec 18, 2026 | 56 | 43.1% | ±13.4% |
| Jan 15, 2027 | 84 | 39.0% | ±14.9% |
| Mar 19, 2027 | 147 | 40.4% | ±20.1% |
| Apr 16, 2027 | 175 | 40.2% | ±21.8% |
| Jun 17, 2027 | 237 | 39.8% | ±25.0% |
| Sep 17, 2027 | 329 | 40.1% | ±29.1% |
30-day implied volatility 46.8% vs 24.5% realized over the last 30 trading days. Put/call ratio (volume) 0.79. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:16 UTC)
| Price | USD 82 |
|---|---|
| Change | ▲ 2.99% (up) |
| Previous Close | USD 79.62 |
| Open | USD 79.9 |
| Day Range | USD 79.91 – 82.29 |
| 52-Week Range | USD 68.77 – 147.93 |
| Volume | 4,827,163 shares |
| Market Cap | $33.88B |
| Exchange | NYQ |
Technical Analysis (ZTS)
Nexqual's technical model rates ZTS "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:16 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.83 (overbought) |
| vs SMA50 | Above (USD 74.48) |
| MACD | 1.99 (positive) |
Analyst Ratings (ZTS)
Wall Street analysts rate ZTS "Buy" based on 17 analysts, with a mean price target of USD 93 (range USD 74–155), per Nexqual as of October 23, 2026 at 09:16 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 93 |
| High Target | USD 155 |
| Low Target | USD 74 |
| Buy / Hold / Sell | 6 / 11 / 0 |
Earnings (ZTS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 1.51 |
| Revenue Estimate | $2.30B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.87 vs est 1.85 ▲ beat |
| 2026-03-31 | USD 1.53 vs est 1.62 ▼ miss |
| 2025-12-31 | USD 1.48 vs est 1.4 ▲ beat |
| 2025-09-30 | USD 1.7 vs est 1.62 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financials & Fundamentals (ZTS)
| Total Revenue | $9.53B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -0.20% |
| Gross Margin | +71.74% |
| Operating Margin | +40.72% |
| Profit Margin | +27.68% |
| ROE | +64.91% |
| Debt / Equity | 2.94 |
| Current Ratio | 3.08 |
| Total Cash | $1.68B |
| Total Debt | $9.26B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $2.32B (24.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financial Health Score (ZTS)
Nexqual rates Zoetis Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:16 UTC.
| Growth | Mixed — Revenue +2.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 41% (last 12 months) |
| Balance Sheet | Weak — $1.68B cash and investments vs $9.05B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $2.32B (last 4 quarters to Jun 2026, SEC), 24% margin |
| Efficiency | Strong — ROE 65%, ROA 15.4% |
Ownership (ZTS)
| Insider Ownership | +0.16% |
|---|---|
| Institutional Ownership | +100.18% |
| Shares Outstanding | 413.22M |
| Float | 412.37M |
| Short % of Float | +5.05% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Leadership (ZTS)
Zoetis Inc. is led by Kristin C. Peck, CEO & Director, per Nexqual as of October 23, 2026 at 09:16 UTC.
| CEO & Director | Kristin C. Peck |
|---|---|
| Executive VP, CFO & COO | James K. Saccaro |
| Vice President of Investor Relations | Steven Frank |
| Executive VP & President of U.S. Commercial Operations | Abhay U. Nayak |
Major Backers & Investors (ZTS)
Notable institutional backers of Zoetis Inc. include State Farm Mutual Automobile Insurance Co, Wellington Management, Morgan Stanley, according to Nexqual as of October 23, 2026 at 09:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| State Farm Mutual Automobile Insurance Co | 3.85% |
| Wellington Management | 2.28% |
| Morgan Stanley | 2.15% |
| Nordea Investment Management AB | 1.6% |
| Fidelity | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 12.07% |
| BlackRock | 9.54% |
| State Street | 4.76% |
| Geode Capital | 3.22% |
| Deutsche Bank AG | 1.42% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
From Zoetis Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our product portfolio enjoys the protection of more than 5,500 granted patents and 1,600 pending patent applications, filed in over 50 countries, with a focus on our major markets, including Australia, Brazil, Canada, China, Europe, Japan and the U.S., as well as other countries with strong patent systems.
- Zoetis enhanced the portfolio of its diagnostic products with the acquisition in 2018 of Abaxis, Inc. (Abaxis), a leading provider of veterinary point-of-care diagnostic instruments, including the Vetscan® portfolio of benchtop and handheld diagnostic instruments and consumables.
- Depending on the nature of the agreement, we may act as the commercialization partner for discoveries that originate during the period of collaborative research, or we may own or have exclusive rights to any intellectual property that enables the development of proprietary products or models.
- We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by seeking to require our employees, consultants, advisors and partners to enter into confidentiality agreements and other arrangements upon the commencement of their employment or engagement.
Partnerships
- In 2024, the company started a collaboration with Blacksmith Medicines to discover and develop novel antibiotics for animal health and provide new options for our customers to treat life-threatening infections in livestock.
Legal & Regulatory Risks (Item 1A, quoted)
- We may incur substantial costs and receive adverse outcomes in litigation and/or other legal matters.
- Our operating results, financial condition and liquidity could be materially adversely affected by unfavorable results in pending or future litigation matters.
- Litigation matters, regardless of their merits or their ultimate outcomes, are costly, divert management's attention and may materially adversely affect our reputation and demand for our products.
- The illegal distribution and sale by third parties of counterfeit or illegally compounded versions of our products or of stolen, diverted or relabeled products could have a negative impact on our reputation and business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HLN | Haleon plc | USD 10.37 | ▲ 3.49% |
| UTHR | United Therapeutics Corporation | USD 584.79 | ▲ 3.78% |
| TEVA | Teva Pharmaceutical Industries | USD 40.21 | ▼ 1.01% |
| VTRS | Viatris Inc. | USD 18.48 | ▲ 0.16% |
| TAK | Takeda Pharmaceutical Company L | USD 20.36 | ▲ 2.16% |
| NBIX | Neurocrine Biosciences, Inc. | USD 143.29 | ▲ 1.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:16 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt